These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36168187)

  • 21. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase.
    Choi EJ
    Blood Res; 2023 Apr; 58(S1):S29-S36. PubMed ID: 36891575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asciminib for chronic myeloid leukaemia: Next questions.
    Shanmuganathan N; Hughes TP
    Br J Haematol; 2022 Nov; 199(3):322-331. PubMed ID: 35729850
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.
    Jiang Q; Li Z; Qin Y; Li W; Xu N; Liu B; Zhang Y; Meng L; Zhu H; Du X; Chen S; Liang Y; Hu Y; Liu X; Song Y; Men L; Chen Z; Niu Q; Wang H; Lu M; Yang D; Zhai Y; Huang X
    J Hematol Oncol; 2022 Aug; 15(1):113. PubMed ID: 35982483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
    Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
    Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results.
    Mauro MJ; Hughes TP; Kim DW; Rea D; Cortes JE; Hochhaus A; Sasaki K; Breccia M; Talpaz M; Ottmann O; Minami H; Goh YT; DeAngelo DJ; Heinrich MC; Gómez-García de Soria V; le Coutre P; Mahon FX; Janssen JJWM; Deininger M; Shanmuganathan N; Geyer MB; Cacciatore S; Polydoros F; Agrawal N; Hoch M; Lang F
    Leukemia; 2023 May; 37(5):1048-1059. PubMed ID: 36949155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib.
    Häselbarth L; Karow A; Mentz K; Böttcher M; Roche-Lancaster O; Krumbholz M; Jitschin R; Mougiakakos D; Metzler M
    Cancer Immunol Immunother; 2023 Jun; 72(6):1661-1672. PubMed ID: 36602564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.
    Schoepfer J; Jahnke W; Berellini G; Buonamici S; Cotesta S; Cowan-Jacob SW; Dodd S; Drueckes P; Fabbro D; Gabriel T; Groell JM; Grotzfeld RM; Hassan AQ; Henry C; Iyer V; Jones D; Lombardo F; Loo A; Manley PW; Pellé X; Rummel G; Salem B; Warmuth M; Wylie AA; Zoller T; Marzinzik AL; Furet P
    J Med Chem; 2018 Sep; 61(18):8120-8135. PubMed ID: 30137981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Next treatment for TKI-resistant CML].
    Takahashi N
    Rinsho Ketsueki; 2023; 64(9):981-987. PubMed ID: 37793874
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
    Yun S; Vincelette ND; Segar JM; Dong Y; Shen Y; Kim DW; Abraham I
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e85-94. PubMed ID: 27101984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
    Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
    Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
    Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
    Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Asciminib in chronic myeloid leukemia.
    Assanto GM; Scalzulli E; Breccia M
    Drugs Today (Barc); 2022 Oct; 58(10):479-489. PubMed ID: 36305542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
    Massaro F; Colafigli G; Molica M; Breccia M
    Expert Rev Hematol; 2018 Apr; 11(4):301-306. PubMed ID: 29522367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.